MRN-1057

MRN-1057 is a preclinical-stage small molecule candidate developed by Agentix Australia that targets the cannabinoid receptor 1 (CB1). It is currently being investigated for the treatment of Type 2 Diabetes (T2D). CB1 receptors are primarily located in the central nervous system and peripheral tissues, where they play a significant role in regulating energy balance, appetite, and metabolic processes. While the specific functional activity (e.g., antagonism vs. agonism) of MRN-1057 has not been explicitly detailed in public pipeline disclosures, the modulation of CB1 signaling is a recognized therapeutic strategy for addressing metabolic disorders by potentially improving insulin sensitivity and glucose homeostasis.